Abstract:
The invention relates to a method of producing mesenchymal stem cell derived exosomes comprising the steps of, performing a method of producing a clonal mesenchymal stem cell line capable of producing exosomes (MSC-derived extracellular vesicles) comprising the steps of, providing human induced pluripotent stem cells (hiPSCs), generating therefrom an immortalized clonal cell line of mesenchymal stem cells (IMSCs), characterizing the potential of the IMSCs to produce exosomes, cultivating the desired IMSCs such that the IMSCs produce exosomes, isolating the exosomes. The invention relates to extracellular vesicles or exosomes, produced according to the invention. The invention relates to the use of these EVs as a medicament and in a pharmaceutical composition.
Abstract:
The present invention pertains to a process for the chromatographic separation of nucleic acid mixtures into their double-stranded and single-stranded nucleic acid fractions by simultaneously absorbing said nucleic acids as a whole to a mineral support, followed by separation into double-stranded and single-stranded nucleic acids by fractional elution, or by selectively absorbing double-stranded or single-stranded nucleic acid of a liquid sample to a mineral support, as well as solutions and a kit for performing the process according to the invention.
Abstract:
The invention relates to a method of producing a clonal mesenchymal stem cell line capable of producing exosomes (MSC-derived extracellular vesicles) comprising the steps of, providing human induced pluripotent stem cells (hiPSCs), generating therefrom an immortalized clonal cell line of mesenchymal stem cells (IMSC), optionally characterizing the potential of the IMSCs to produce exosomes. The invention also relates to a stem cell line produced according to the invention. The invention relates to the cell line according to the invention, for use as a medicament. The invention relates to the cell line according to the invention for use in treating a disease that is amenable to treatment with stem cell therapy. The invention also relates to the use of a stem cell line according to the invention for producing EVs.
Abstract:
A process for the depletion or removal of endotoxins from preparations containing active ingredients designated for therapeutical use which are obtained from natural sources by genetic engineering and/or biotechnology by treatment with chromatographic material wherein said natural sources are lysed, the fractions obtained are optionally centrifuged, filtrated or treated with affinity chromatographic methods; said fractions are preincubated with an aqueous salt solution and detergents, treated with anion exchange material and then washed with another salt solution, and the active ingredients are eluted from the anion exchanger, followed by further purification in a per se known manner.
Abstract:
A process for the isolation and purification of nucleic acids and/or oligonucleotides for use in gene therapy wherein said nucleic acids and/or oligonucleotides are isolated or purified from an essentially biological source, characterized in that said essentially biological sources are lysed, the fractions obtained are optionally freed or depleted from the remainder of said biological sources by per se known mechanical methods, such as centrifugation, filtration; the fractions thus treated are subsequently treated with affinity chromatographic material or with inorganic chromatographic material for the removal of endotoxins; followed by isolation of said nucleic acids and/or oligonucleotides on an anion exchanger which is designed such that DNA begins to desorb from the anion exchanger only at an ionic strength corresponding to a sodium chloride solution of a concentration higher by at least 100 mM than one corresponding to the ionic strength at which RNA begins to desorb from the anion exchanger material.
Abstract:
Described is a method of isolating cell components, such as nucleic acids, from natural sources by filtering a sample of the digested natural sources such as cells or cell fragments. The method is characterized in that the sample is passed through a filter, the pore size of which decreases in the direction of flow of the sample through the filter.
Abstract:
A filtration process for the preparation of nucleic acids from natural sources is disclosed. The sources containing nucleic acids are lysed; the lysate is left to rest for some time; the resulting lysate passes a filter layer. The filter layer is selected from silica gel, aluminum oxide or packed diatomaceous earth, or interwoven or cemented non-wovens of glass fibers and silica gel. Other filter layers include cellulose, paper, compressed paper, and paper non-wovens. The fraction leaving the filter layer is then collected and the nucleic acid is subsequently isolated and purified from the collected fraction. Furthermore, the filter layer has not been modified with anion exchange groups.
Abstract:
A process for the isolation and purification of nucleic acids and/or oligonucleotides for use in gene therapy wherein nucleic acids and/or oligonucleotides are isolated or purified from an essentially biological source, characterized in thatessentially biological sources are lysed, the fractions obtained are optionally freed or depleted from the remainder of biological sources by per se known mechanical methods, such as centrifugation, filtration;the fractions thus treated are subsequently treated with affinity chromatographic material or with inorganic chromatographic material for the removal of endotoxins; followed byisolation of nucleic acids and/or oligonucleotides on an anion exchanger which is designed such that DNA begins to desorb from the anion exchanger only at an ionic strength corresponding to a sodium chloride solution of a concentration higher by at least 100 mM than one corresponding to the ionic strength at which RNA begins to desorb from the anion exchanger material.
Abstract:
The invention relates to a method and a device for performing a nucleic acid preparation and/or amplification.For the implementation of the method, a flexible tube is provided, which is always sealed below and hence at one end during the implementation of the sample preparation and/or amplification. In this tube, a biological sample is prepared and/or amplified. The use of only one tube is very economical. The tube is a disposable item which after a preparation or amplification can with its contents be disposed of environmentally correctly. Since moreover the tube has only to be filled with sample substances and reagents at a given time and manipulated, the method can also be simply and economically performed automatically.
Abstract:
The present invention pertains to a process for the chromatographic separation of nucleic acid mixtures into their double-stranded and single-stranded nucleic acid fractions by simultaneously absorbing said nucleic acids as a whole to a mineral support, followed by separation into double-stranded and single-stranded nucleic acids by fractional elution, or by selectively absorbing double-stranded or single-stranded nucleic acid of a liquid sample to a mineral support, as well as solutions and a kit for performing the process according to the invention.